Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free ALVO Stock Alerts

Alvotech (ALVO) Competitors

Alvotech logo
$4.43 +0.16 (+3.75%)
As of 08/21/2026 04:00 PM Eastern
Compare

ALVO vs. EWTX, PBLS, CELC, RLAY, and ELVN

Should you buy Alvotech stock or one of its competitors? Alvotech's main competitors and comparable companies include Edgewise Therapeutics (EWTX), Parabilis Medicines (PBLS), Celcuity (CELC), Relay Therapeutics (RLAY), and Enliven Therapeutics (ELVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alvotech compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Alvotech (NASDAQ:ALVO) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Edgewise Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -36.31%. Alvotech's return on equity of -11.92% beat Edgewise Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Edgewise TherapeuticsN/A -39.01% -36.96%
Alvotech -36.31%-11.92%-11.73%

Alvotech has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edgewise TherapeuticsN/AN/A-$167.79M-$1.85N/A
Alvotech$588.90M2.27$27.92M-$0.61N/A

Edgewise Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market.

In the previous week, Alvotech had 12 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 19 mentions for Alvotech and 7 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.16 beat Alvotech's score of 0.16 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Edgewise Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alvotech
3 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Edgewise Therapeutics presently has a consensus target price of $50.33, suggesting a potential upside of 13.93%. Alvotech has a consensus target price of $7.60, suggesting a potential upside of 71.56%. Given Alvotech's higher possible upside, analysts clearly believe Alvotech is more favorable than Edgewise Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edgewise Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Alvotech
2 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.14

Summary

Alvotech beats Edgewise Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Alvotech compare to Parabilis Medicines?

Alvotech (NASDAQ:ALVO) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Parabilis Medicines has a net margin of 0.00% compared to Alvotech's net margin of -36.31%. Parabilis Medicines' return on equity of 0.00% beat Alvotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Alvotech-36.31% -11.92% -11.73%
Parabilis Medicines N/A N/A N/A

Alvotech has higher revenue and earnings than Parabilis Medicines.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$588.90M2.27$27.92M-$0.61N/A
Parabilis MedicinesN/AN/AN/AN/AN/A

Alvotech currently has a consensus price target of $7.60, suggesting a potential upside of 71.56%. Parabilis Medicines has a consensus price target of $41.67, suggesting a potential upside of 5.86%. Given Alvotech's higher probable upside, equities analysts clearly believe Alvotech is more favorable than Parabilis Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alvotech
2 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.14
Parabilis Medicines
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, Alvotech had 15 more articles in the media than Parabilis Medicines. MarketBeat recorded 19 mentions for Alvotech and 4 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.41 beat Alvotech's score of 0.16 indicating that Parabilis Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alvotech
3 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Parabilis Medicines
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Parabilis Medicines beats Alvotech on 7 of the 10 factors compared between the two stocks.

How does Alvotech compare to Celcuity?

Alvotech (NASDAQ:ALVO) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Alvotech currently has a consensus target price of $7.60, indicating a potential upside of 71.56%. Celcuity has a consensus target price of $154.55, indicating a potential upside of 65.24%. Given Alvotech's higher probable upside, analysts clearly believe Alvotech is more favorable than Celcuity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alvotech
2 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.14
Celcuity
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

Celcuity has a net margin of 0.00% compared to Alvotech's net margin of -36.31%. Alvotech's return on equity of -11.92% beat Celcuity's return on equity.

Company Net Margins Return on Equity Return on Assets
Alvotech-36.31% -11.92% -11.73%
Celcuity N/A -350.78%-41.54%

63.3% of Celcuity shares are owned by institutional investors. 0.5% of Alvotech shares are owned by insiders. Comparatively, 13.3% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Alvotech had 9 more articles in the media than Celcuity. MarketBeat recorded 19 mentions for Alvotech and 10 mentions for Celcuity. Celcuity's average media sentiment score of 0.30 beat Alvotech's score of 0.16 indicating that Celcuity is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alvotech
3 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Celcuity
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Alvotech has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$588.90M2.27$27.92M-$0.61N/A
CelcuityN/AN/A-$177.04M-$4.30N/A

Alvotech has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

Summary

Alvotech beats Celcuity on 8 of the 15 factors compared between the two stocks.

How does Alvotech compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Alvotech (NASDAQ:ALVO) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Relay Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market.

97.0% of Relay Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by company insiders. Comparatively, 0.5% of Alvotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Relay Therapeutics currently has a consensus price target of $25.92, indicating a potential upside of 33.32%. Alvotech has a consensus price target of $7.60, indicating a potential upside of 71.56%. Given Alvotech's higher possible upside, analysts clearly believe Alvotech is more favorable than Relay Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Relay Therapeutics
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
2.93
Alvotech
2 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.14

Relay Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -36.31%. Alvotech's return on equity of -11.92% beat Relay Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Relay TherapeuticsN/A -42.27% -38.67%
Alvotech -36.31%-11.92%-11.73%

Alvotech has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relay Therapeutics$15.35M277.53-$276.48M-$1.57N/A
Alvotech$588.90M2.27$27.92M-$0.61N/A

In the previous week, Relay Therapeutics had 5 more articles in the media than Alvotech. MarketBeat recorded 24 mentions for Relay Therapeutics and 19 mentions for Alvotech. Relay Therapeutics' average media sentiment score of 0.85 beat Alvotech's score of 0.16 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Relay Therapeutics
8 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alvotech
3 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Relay Therapeutics beats Alvotech on 10 of the 17 factors compared between the two stocks.

How does Alvotech compare to Enliven Therapeutics?

Alvotech (NASDAQ:ALVO) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Alvotech has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$588.90M2.27$27.92M-$0.61N/A
Enliven TherapeuticsN/AN/A-$103.69M-$1.67N/A

Alvotech has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Alvotech currently has a consensus target price of $7.60, indicating a potential upside of 71.56%. Enliven Therapeutics has a consensus target price of $75.00, indicating a potential upside of 25.38%. Given Alvotech's higher probable upside, equities analysts plainly believe Alvotech is more favorable than Enliven Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alvotech
2 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.14
Enliven Therapeutics
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78

95.1% of Enliven Therapeutics shares are held by institutional investors. 0.5% of Alvotech shares are held by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Enliven Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -36.31%. Alvotech's return on equity of -11.92% beat Enliven Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alvotech-36.31% -11.92% -11.73%
Enliven Therapeutics N/A -18.55%-18.09%

In the previous week, Alvotech had 4 more articles in the media than Enliven Therapeutics. MarketBeat recorded 19 mentions for Alvotech and 15 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.66 beat Alvotech's score of 0.16 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alvotech
3 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Enliven Therapeutics
4 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Alvotech beats Enliven Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Alvotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALVO vs. The Competition

Export
MetricAlvotechBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.34B$4.01B$7.37B$12.85B
Dividend YieldN/A3.64%2.53%11.08%
P/E Ratio-7.2611.62272.6024.24
Price / Sales2.271,338.17618.9699.81
Price / Cash20.33105.1478.6253.99
Price / Book-7.0316.8013.056.20
Net Income$27.92M-$12.50M$3.47B$348.59M
7 Day Performance9.38%3.29%2.09%0.08%
1 Month Performance39.31%8.23%6.64%3.88%
1 Year Performance-47.57%55.05%25.02%16.98%

Alvotech Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALVO
Alvotech
2.8261 of 5 stars		$4.43
+3.7%		$7.60
+71.6%		-47.6%$1.34B$588.90MN/A1,460
EWTX
Edgewise Therapeutics
2.8056 of 5 stars		$43.90
-0.3%		$49.08
+11.8%		+197.5%$4.77BN/AN/A60
PBLS
Parabilis Medicines
2.084 of 5 stars		$39.50
+6.1%		$41.67
+5.5%		N/A$4.67B$148KN/AN/A
CELC
Celcuity
3.4037 of 5 stars		$93.62
+1.3%		$154.55
+65.1%		+78.4%$4.57BN/AN/A40
RLAY
Relay Therapeutics
3.3876 of 5 stars		$20.54
-0.6%		$25.83
+25.8%		+426.8%$4.50B$10.35MN/A330

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ALVO) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel